This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of those who spoke  and presented posters at the meeting contributed to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best� and “most important� meetings in the field. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations were described, there will be many new topics that either are in their infancy or did not exist at the time of the last RD Symposium. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those were reported at the RD2016 meeting and included in the current volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations is reflected in the volume. 

The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

This book will contain the proceedings of the XV International Symposium on Retinal Degeneration (RD2012). A majority of those who will speak and present posters at the meeting will contribute to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2010. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2010 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

This book will contain the proceedings of the XIV International Symposium on Retinal Degeneration (RD2010), held July 13-17, 2010, in Mont-Tremblant, Quebec, Canada. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.

This book will contain the proceedings of the XV International Symposium on Retinal Degeneration (RD2012). A majority of those who will speak and present posters at the meeting will contribute to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2010. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2010 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

Reading without meditation is sterile; meditation without reading is liable to error; prayer without meditation is lukewarm; meditation without prayer is unfruitful; prayer, when it is fervent, wins contemplation, but to obtain contemplation without prayer would be rare, even miraculous. Bernhard de Clairvaux (12th century) NobodycandenythatIP-basedtra?chasinvadedourdailylifeinmanyways and no one can escape from its di?erent forms of appearance. However, most people are not aware of this fact. From the usage of mobile phones - either as simple telephone or for data transmissions - over the new form of telephone service Voice over IP (VoIP), up to the widely used Internet at the users own PC, in all instances the transmission of the information, encoded in a digital form, relies on the Internet Protocol (IP). So, we should take a brief glimpse at this protocol and its constant companions such as TCP and UDP, which have revolutionized the communication system over the past 20 years. The communication network has experienced a fundamental change, which was dominated up to end of the eighties of the last century by voice appli- tion.Butfromthemiddleoftheninetieswehaveobservedadecisivemigration in the data transmission. If the devoted reader of this monograph reads the title 'IP tra?c theory and performance', she/he may ask, why do we have to be concerned with mod- ing IP tra?c, and why do we have to consider and get to know new concepts.

Reading without meditation is sterile; meditation without reading is liable to error; prayer without meditation is lukewarm; meditation without prayer is unfruitful; prayer, when it is fervent, wins contemplation, but to obtain contemplation without prayer would be rare, even miraculous. Bernhard de Clairvaux (12th century) NobodycandenythatIP-basedtra?chasinvadedourdailylifeinmanyways and no one can escape from its di?erent forms of appearance. However, most people are not aware of this fact. From the usage of mobile phones - either as simple telephone or for data transmissions - over the new form of telephone service Voice over IP (VoIP), up to the widely used Internet at the users own PC, in all instances the transmission of the information, encoded in a digital form, relies on the Internet Protocol (IP). So, we should take a brief glimpse at this protocol and its constant companions such as TCP and UDP, which have revolutionized the communication system over the past 20 years. The communication network has experienced a fundamental change, which was dominated up to end of the eighties of the last century by voice appli- tion.Butfromthemiddleoftheninetieswehaveobservedadecisivemigration in the data transmission. If the devoted reader of this monograph reads the title 'IP tra?c theory and performance', she/he may ask, why do we have to be concerned with mod- ing IP tra?c, and why do we have to consider and get to know new concepts.

This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of those who spoke and presented posters at the meeting contributed to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations were described, there will be many new topics that either are in their infancy or did not exist at the time of the last RD Symposium, RD2016. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those were reported at the RD2016 meeting and included in the current volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations is reflected in the volume.

This book constitutes the refereed proceedings of the First Multidisciplinary International Symposium, MISDOOM 2019, held in Hamburg, Germany, in February/March 2019. The 14 revised full papers were carefully reviewed and selected from 21 submissions. The papers are organized in topical sections named: human computer interaction and disinformation, automation and disinformation, media and disinformation.

This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of those who spoke and presented posters at the meeting contributed to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations were described, there will be many new topics that either are in their infancy or did not exist at the time of the last RD Symposium, RD2016. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those were reported at the RD2016 meeting and included in the current volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations is reflected in the volume.

This book constitutes the refereed proceedings of the 9th International Conference on Evolutionary Multi-Criterion Optimization, EMO 2017 held in Munster, Germany in March 2017. The 33 revised full papers presented together with 13 poster presentations were carefully reviewed and selected from 72 submissions. The EMO 2017 aims to discuss all aspects of EMO development and deployment, including theoretical foundations; constraint handling techniques; preference handling techniques; handling of continuous, combinatorial or mixed-integer problems; local search techniques; hybrid approaches; stopping criteria; parallel EMO models; performance evaluation; test functions and benchmark problems; algorithm selection approaches; many-objective optimization; large scale optimization; real-world applications; EMO algorithm implementations.

Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), to be held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who will speak and present posters at the meeting will contribute to this volume. The Symposium addresses the blinding diseases of inherited retinal degenerations, which have no effective treatments and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations will be included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances will be presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2014 meeting and included.

Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), to be held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who will speak and present posters at the meeting will contribute to this volume. The Symposium addresses the blinding diseases of inherited retinal degenerations, which have no effective treatments and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations will be included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances will be presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2014 meeting and included.

This book will contain the proceedings of the XIV International Symposium on Retinal Degeneration (RD2010), held July 13-17, 2010, in Mont-Tremblant, Quebec, Canada. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.

Masterarbeit aus dem Jahr 2006 im Fachbereich Philosophie - Philosophie des 20. Jahrhunderts / Gegenwart, Note: 2.5, FernUniversitat Hagen (Philosophie), 40 Quellen im Literaturverzeichnis, Sprache: Deutsch, Anmerkungen: Gutachter 1: (Bewertung: 1.7) Gutachter 2: (Bewertung 3.3) gesamtnote: 2.5, Abstract: Infolge der Innovationen und Entwicklungen in der Biotechnologie, Gentechnik und Biomedizin steht die Menschheit vor einer Vielzahl von ungelosten ethischen Fragen und Problemen. Technische Innovationen stellen die bisherigen Definitionen von Leben und Tod auf den Prufstand. Reanimations- und Transplantationstechnologien verschieben die Grenzen von Leben und Tod, Reproduktionsmedizin, embryonale Stammzellforschung und therapeutisches Klonen zwingen zu einer Reevaluierung von Leben und Recht auf Leben. Ob Komapatienten oder uberzahlige" Embryonen, wir sehen uns konfrontiert mit einer neuen Form von menschlichem Leben, Leben im Ausnahmezustand." Giorgio Agamben spricht in diesem Sinne von neomorts" und faux vivants" Der Reanimationsraum, in dem der neomort," der Ultrakomatose" und der faux vivant" zwischen Leben und Tod schwanken, bildet einen Raum der Ausnahme, in dem das nackte Leben im Reinzustand erscheint, zum ersten Mal vollstandig vom Menschen und seiner Technologie kontrolliert." Agamben sieht die Machte, die den Menschen im Ausnahmezustand, den homo sacer, zur Regel machen, verkorpert in einer Biopolitik," die die individuelle Existenz bis ins Verborgenste bestimmen mochte. Ziel der vorliegenden Arbeit ist es, den Begriff der Biopolitik bei Agamben - unter Miteinbeziehung des Begriffs der Biopolitik bzw. Biomacht bei Michel Foucault - hinsichtlich seiner Bedeutung fur die modernen Biowissenschaften zu untersuchen. Hierzu soll zunachst ein Uberblick uber Forschungsstand und aktuelle Entwicklungen in der Biomedizin, insbesondere in der embryonalen Stammzellforschung und in der Reproduktionsm

Studienarbeit aus dem Jahr 2005 im Fachbereich Philosophie - Philosophie der Antike, Note: 2.0, FernUniversitat Hagen, 27 Quellen im Literaturverzeichnis, Sprache: Deutsch, Abstract: "The safest generalization that can be made about the history of western philosophy is that it is all a series of footnotes to Plato." Dieser Satz von Whitehead ist weithin bekannt und in der Tat, von Aristoteles bis Cicero, von Plotin bis Augustinus, von Machiavelli bis Nietzsche, von Popper bis Gadamer, kaum ein westlicher Philosoph, der nicht auf Platon bezug nahme. Im Zentrum von Rezeption und Diskussion stehen v.a. der ideale Staat" wie er in der Politea entwickelt wird und das Konzept der Ideen selbst, die Ideenlehre" als Kern der platonischen Philosophie. Nach Aristoteles war es v.a. Heraklits Auffassung, dass alles in der Welt der Erscheinungen im Fluss sei, die Platon und spater auch seine Anhanger nachhaltig pragte und zum Konzept der Ideen fuhrte. Aristoteles Darstellung wird zwar kontrovers diskutiert, unbestreitbar scheint jedoch, was auch immer Platon zur Annahme der Ideen letztlich veranlasst haben mag, die Vorstellung einer veranderlichen Welt im Fluss ohne irgendetwas Bestandiges, Ewiges, Unveranderliches, ist nicht spurlos an ihm vorrubergegangen. Im Dialog Kratylos etwa lasst er Sokrates sagen: Ja es ist nicht einmal moglich zu sagen, dass es eine Erkenntnis gebe, wenn alle Dinge sich verwandeln und nichts bleibt...und von diesem Satze aus gibt es weder ein Erkennendes noch ein zu Erkennendes. Ist aber immer das Erkennende und das Erkannte, ist das Schone, ist das Gute, ist jegliches Seiende, so scheint mir dies, wie wir es jetzt sagen, gar nicht mehr einem Fluss ahnlich oder einer Bewegung. Ob nun dieses sich so verhalt oder vielmehr so, wie Herakleitos mit den Seinigen und noch viele andere behaupten, das mag wohl gar nicht leicht sein, zu untersuchen." Mit der Annahme von ewigen und unveranderlichen Ideen hinter den Erscheinungen suchte Platon einen Ausgleich zu s

Studienarbeit aus dem Jahr 2004 im Fachbereich Philosophie - Philosophie des 17. und 18. Jahrhunderts, Note: gut, FernUniversitat Hagen (Philosophie), Sprache: Deutsch, Abstract: Im Jahre 1514 schlug der polnische Astronom Nikolaus Kopernikus ein Modell der Welt' vor mit der Sonne als Mittelpunkt, um den sich die Erde und die Planeten in kreisformigen Umlaufbahnen bewegten. Die Kopernikanische Wende' in diesem Sinne bezeichnet somit die Ablosung des aristotelisch-ptolemaischen Weltbildes mit der Erde als Mittelpunkt (Geozentrismus) durch das heliozentrische Weltbild, ein nachhaltiger Bruch mit der damals vertretenen Lehrmeinung. In seiner zweiten Vorrede zur Kritik der reinen Vernunft stellte Kant eine Analogie zur Metaphysik her, indem er forderte, dass sich nicht mehr all unsere Erkenntnis nach den Gegenstanden richten durfe, sondern, dass sich der Gegenstand (als Objekt der Sinne) nach der Beschaffenheit unseres Anschauungsvermogens" richten musse. Damit begrundete Kant eine neue Stellung des Subjekts zur Objektivitat." Durch den perspektivischen Wechsel wird das erkennende Subjekt zum eigentlichen Gegenstand der Metaphysik und der transzendentale, also Erkenntnis zuallererst ermoglichende Wert des Objekts, minimiert. Die Metaphysik Kants stellt also nicht mehr die Frage nach Transzendentem," Erfahrungsjenseitigem, sondern nach Transzendentalem," nach den Bedingungen und Grenzen der Moglichkeit von Erkenntnis uberhaupt. Kants kritisches Anliegen ist die Vernunft selbst, Kritik an der Vernunft und Kritik durch die Vernunft. Die Kritik der reinen Vernunft will die Grenzen des Erkenntnisvermogens ziehen und wenn man das Resultat der kopernikanischen Revolution, die Trennung von Erscheinung und Ding an sich," anerkennt und die objektive Erkenntnis auf den Bereich moglicher Erfahrung einschrankt," stellt sich konsequenterweise die Frage nach den Auswirkungen auf die Probleme bzw. grossen Fragen der Metaphysik, mit denen sich Kant auseinandergesetzt hat, insbe